Abbreviations: Ara-C = cytarabine; ATG = anti-thymocyte globulin; Bu = busulfan; CNS = central nervous system; CY/CTX = cyclophosphamide; Flu = fludarabine; IDA = idarubicin; NHL = non Hodgkin lymphoma; SAA = severe aplastic anemia; PTLD = post-transplant lymphoproliferative disorder; VP-16 = etoposide.
EBV-associated post-transplant lymphoproliferative disorder (PTLD) is a lift-threatening complication in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT).
1,2 The incidence of PTLD ranges from 0.2 to 22% in allo-HSCT recipients, depending on the number of risk factors. 3, 4 Although the introduction of rituximab as a first-line treatment has improved outcome of PTLD, PTLD with central nervous system (CNS-PTLD) involvement still has a dismal prognosis because of low penetrance of rituximab across the blood-brain barrier. [5] [6] [7] In this prospective study, we reported the successful treatment with intrathecal rituximab in CNS-PTLD who had failed to respond to the IV rituximab-based treatments.
From June 2009 to November 2013, 32 cases of EBV-associated PTLD were recorded in the Southern Medical University Institute of Hematology. Fourteen patients diagnosed with CNS-PTLD were enrolled in this prospective study, including 10 peripheral PTLD accompanying with CNS involvement and four primitive CNS-PTLD, at a median time of 60 (29-186) days after allo-HSCT. Antithymocyte globulin was used in 10 patients undergoing HLAmismatched or unrelated donor transplantation and 3 patients with severe aplastic anemia. Most of the peripheral PTLD with CNS involvement patients (n = 9) initially presented with systemic signs and symptoms, such as fever and lymphadenectasis, followed by CNS manifestations within 1 week. The manifestations of primitive CNS-PTLD were fever and CNS presentations, including headache, hyperspasmia, memory impairment and light coma. The characteristics of the 14 patients with CNS-PTLD are summarized in Table 1 .
The study was performed in accordance with the modified Helsinki Declaration, and the protocol was approved by the institute ethics review boards before study initiation. Written informed consents were obtained from each patient before invasive procedures and treatments. The evaluation of treatment response was based on the international workshop standardized response criteria for primary CNS lymphoma. 8 Complete response (CR) requires the following: (1) EBV-DNA levels in CSF. The failure of initial treatment was defined as CNS-PTLD progressing within 1 week after the IV rituximabbased treatments.
The study treatments included reducing immunosuppression and rituximab-based treatments followed by adoptive cellular immunotherapy. Immunosuppressants were withdrawn in a stepwise fashion (total dose reduced by 20%/week) if possible. Rituximab alone (375 mg/m 2 weekly, four doses as one cycle with an interval of 2 weeks) or rituximab combined with chemotherapy (R-COP: rituximab+ cyclophosphamide+vincristine+ prednisolone or R-CHOP: R-COP+ doxorubicin, every 4 weeks) were given based on PTLD histopathology and blood counts. Generally, rituximab monotherapy was administrated in the patients with early lesions or peripheral WBC platelet o50 × 10 9 /L, which was decided by the attending physician. For the patients who failed to respond to the initial IV rituximab-based treatments, sequential doseescalation schedule of intrathecal rituximab (initial dose of 20 mg, increased by 10 mg each week and maximum dose of 50 mg) plus dexamethasone (10 mg) was administrated weekly. If patients did not obtain CR after 2 cycles of the rituximab-based treatments, donor lymphocyte infusion (DLI) would be added as a salvage treatment. 9 For the consolidation of CR, DLI was given at a median dose of 2 × 10 7 CD3 + T cells/kg if the patient had availability of the original donor and no pre-existing GVHD, and EBV-specific cytotoxic T lymphocytes (EBV-CTLs) were given at a median dose of 1 × 10 6 cells/kg if the patient had pre-existing GVHD or a lack of original donor.
In the initial treatments, 14 patients all underwent reducing immunosuppression, 9 patients received rituximab monotherapy and 5 patients received rituximab combined with chemotherapy, including 2 R-COP and 3 R-CHOP. Three patients were responsive and 11 were unresponsive to the initial treatments within 1 week. For the 11 patients who failed to respond to the initial treatments, 9 patients received intrathecal rituximab within 7-11 days and 2 patients refused. After two cycles of rituximab-based treatments, 10 patients (3 received IV rituximab and 7 received the combination of IV and intrathecal rituximab) achieved CR, 2 patients were partial responders and 2 patients were nonresponders. DLI was added as a salvage treatment in 2 patients, wherein one achieved CR and the other died of PTLD progressing. The two patients without intrathecal rituximab died of PTLD progressing on 4 and 18 days after disease onset, respectively. To prevent PTLD relapse, a total of 21 doses of DLI or EBV-CTLs were administered in 9 CR patients, including 15 doses of DLI in seven cases, and 6 doses of EBV-CTLs in two cases. The other 2 CR patients, including 1 developed acute GVHD (aGVHD) and 1 died of CMV pneumonia, did not receive adoptive cellular immunotherapy. After the reduction of immunosuppressants, 9 patients developed aGVHD (grade I, n = 5; grade II, n = 3; grade III, n = 1). Six patients were cleared with therapy, while the patient with grade III aGVHD merged into extensive chronic GVHD (cGVHD), and died of GVHD. Of the eight patients receiving DLI, three developed aGVHD (grade I, n = 2; grade II, n = 1), and two developed cGVHD (one limited and one extensive), respectively. The two patients receiving EBV-CTLs did not develop de novo aGVHD or cGVHD or a flare of pre-existing GVHD after the treatments. Until now, only one patient experienced peripheral PTLD recurrence on 907 days after the diagnosis of CNS-PTLD.
With a median follow-up of 664 (range 4-1545) days after the diagnosis of CNS-PTLD, seven patients survived and seven died. The causes of death included PTLD progressing (n = 3), PTLD relapse (n = 1), GVHD (n = 1), CMV pneumonia (n = 1) and Pseudomonas aeruginosa sepsis (n = 1). The treatment outcome of CNS-PTLD is shown in Table 2 .
Several studies documented that CNS involvement occurred in 10-20% of PTLD, and primitive CNS-PTLD was not rare. 1, 10, 11 In our cohort, 35.7% (10/28) peripheral PTLD had CNS involvement which was higher as compared with the reports. 1, 11 A rational interpretation is that we pay close attention to EBV-associated CNS diseases. In this study, CSF analysis and neuroimaging were routinely performed on patients with EBV-associated diseases or with unexplainable CNS manifestations after allo-HSCT. One patient was diagnosed as CNS-PTLD before the CNS manifestations, and four primitive CNS-PTLD were diagnosed on the basis of CSF analysis and CNS magnetic resonance imaging. These results supported our interpretation.
Rituximab has been used as a front-line treatment for EBVassociated PTLD, with a CR rate around 60%. 5, 6, 12 Unfortunately, IV rituximab is poorly effective against CNS-PTLD because of low penetrance across the blood-brain barrier. [13] [14] [15] In this study, only 3 of 14 patients were responsive to the IV rituximab-based treatments, which was consistent with the reports. 6, 7 Recently, a few studies demonstrated that intrathecal administration of rituximab was an effective and safe method for pediatric CNS-PTLD. 7, 14 Czyzewski, et al. 14 reported that seven of eight children with CNS-PTLD were responsive to intrathecal rituximab. Letter to the Editor Bonney et al. 7 documented successful management of intrathecal rituximab in two pediatric primitive CNS-PTLD following the failure of IV rituximab. In adults, the data on intrathecal rituximab administration of CNS-PTLD are limited. To our knowledge, this is the largest series of adult CNS-PTLD treated with intrathecal rituximab in the recipients of allo-HSCT. Our results showed that intrathecal rituximab was effective in eight of nine patients who had failed to respond to IV rituximab-based treatments. Intrathecal rituximab was well-tolerated in this study, only two patients presented temporary headache and cauda equina syndrome immediately after the treatment. With a median follow-up of 24 (18-51) months in the seven alive patients, none of the long-term adverse events associated with intrathecal rituximab was recorded. In addition, DLI was added as a salvage treatment in two patients, wherein one achieved CR and the other died of PTLD progressing. To prevent the recurrence of PTLD, adoptive cellular immunotherapy was used as an intensive consolidation treatment. Although none of the patients developed grade 3-4 aGVHD after DLI or EBV-CTLs. We presumed the low occurrence of severe GVHD might be associated with the prior rituximab administration. Until now, only one patient experienced peripheral PTLD relapse. The recurrence rate was lower as compared with the reported literature. 5 In conclusion, intrathecal rituximab is an effective and safe method for treating CNS-PTLD in the recipients of allo-HSCT who were unresponsive to the IV rituximab-based treatments. Because of the small number patients, the optimal strategy of intrathecal rituximab administration remains to be studied.
